{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:51:24Z","timestamp":1771649484021,"version":"3.50.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007470","name":"Shaqra University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007470","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11033-024-09575-6","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T14:02:26Z","timestamp":1715176946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A new perspective on therapies involving B-cell depletion in autoimmune diseases"],"prefix":"10.1007","volume":"51","author":[{"given":"Sulieman Ibraheem Shelash","family":"Al-Hawary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saade Abdalkareem","family":"Jasim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Hjazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himayat","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahamedha","family":"Deorari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. B.","family":"Sapaev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Ali","family":"Ami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karrar Hatif","family":"Mohmmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munther Kadhim","family":"Abosaoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"key":"9575_CR1","volume":"12","author":"F Angum","year":"2020","unstructured":"Angum F, Khan T, Kaler J, Siddiqui L, Hussain A (2020) The prevalence of autoimmune disorders in women: a narrative review. Cureus 12:e8094","journal-title":"Cureus"},{"key":"9575_CR2","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103236","volume":"22","author":"K Bieber","year":"2023","unstructured":"Bieber K, Hundt JE, Yu X, Ehlers M, Petersen F, Karsten CM, K\u00f6hl J, Kridin K, Kalies K, Kasprick A (2023) Autoimmune pre-disease. Autoimmun Rev 22:103236","journal-title":"Autoimmun Rev"},{"key":"9575_CR3","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1007\/s00018-016-2311-1","volume":"73","author":"S J\u00f6rg","year":"2016","unstructured":"J\u00f6rg S, Grohme DA, Erzler M, Binsfeld M, Haghikia A, M\u00fcller DN, Linker RA, Kleinewietfeld M (2016) Environmental factors in autoimmune diseases and their role in multiple sclerosis. Cell Mol Life Sci 73:4611\u20134622","journal-title":"Cell Mol Life Sci"},{"key":"9575_CR4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","volume":"19","author":"DS Pisetsky","year":"2023","unstructured":"Pisetsky DS (2023) Pathogenesis of autoimmune disease. Nat Rev Nephrol 19:509\u2013524","journal-title":"Nat Rev Nephrol"},{"key":"9575_CR5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","volume":"21","author":"GC Tsokos","year":"2020","unstructured":"Tsokos GC (2020) Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol 21:605\u2013614","journal-title":"Nat Immunol"},{"key":"9575_CR6","volume":"22","author":"Y Park","year":"2022","unstructured":"Park Y, Kwok SK (2022) Recent advances in cell therapeutics for systemic autoimmune diseases. Immune Netw 22:e10","journal-title":"Immune Netw"},{"key":"9575_CR7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DS Lee","year":"2021","unstructured":"Lee DS, Rojas OL, Gommerman JL (2021) B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discovery 20:179\u2013199","journal-title":"Nat Rev Drug Discovery"},{"key":"9575_CR8","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1626","volume":"14","author":"M Barberis","year":"2024","unstructured":"Barberis M, Rojas L\u00f3pez A (2024) Metabolic imbalance driving immune cell phenotype switching in autoimmune disorders: tipping the balance of T-and B-cell interactions. Clin Transl Med 14:e1626","journal-title":"Clin Transl Med"},{"key":"9575_CR9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/JIR.S286426","volume":"14","author":"E Chekol Abebe","year":"2021","unstructured":"Chekol Abebe E, Asmamaw Dejenie T, Mengie Ayele T, Dagnew Baye N, Agegnehu Teshome A, Tilahun Muche Z (2021) The role of regulatory B cells in health and diseases: a systemic review. J Inflamm Res 14:75\u201384","journal-title":"J Inflamm Res"},{"key":"9575_CR10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.coi.2019.09.004","volume":"61","author":"JL Barnas","year":"2019","unstructured":"Barnas JL, Looney RJ, Anolik JH (2019) B cell targeted therapies in autoimmune disease. Curr Opin Immunol 61:92\u201399","journal-title":"Curr Opin Immunol"},{"key":"9575_CR11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","volume":"17","author":"MT Cencioni","year":"2021","unstructured":"Cencioni MT, Mattoscio M, Magliozzi R, Bar-Or A, Muraro PA (2021) B cells in multiple sclerosis\u2014from targeted depletion to immune reconstitution therapies. Nat Rev Neurol 17:399\u2013414","journal-title":"Nat Rev Neurol"},{"key":"9575_CR12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25927","volume":"89","author":"G Comi","year":"2021","unstructured":"Comi G, Bar-Or A, Lassmann H, Uccelli A, Hartung HP, Montalban X, S\u00f8rensen PS, Hohlfeld R, Hauser SL, Foundation EPottAMotEC (2021) Role of B cells in multiple sclerosis and related disorders. Ann Neurol 89:13\u201323","journal-title":"Ann Neurol"},{"key":"9575_CR13","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1172\/JCI70972","volume":"123","author":"F Montalvao","year":"2013","unstructured":"Montalvao F, Garcia Z, Celli S, Breart B, Deguine J, Van Rooijen N, Bousso P (2013) The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J Clin Invest 123:5098\u20135103","journal-title":"J Clin Invest"},{"key":"9575_CR14","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s10067-020-04996-7","volume":"39","author":"L Bergantini","year":"2020","unstructured":"Bergantini L, d\u2019Alessandro M, Cameli P, Vietri L, Vagaggini C, Perrone A, Sestini P, Frediani B, Bargagli E (2020) Effects of rituximab therapy on B cell differentiation and depletion. Clin Rheumatol 39:1415\u20131421","journal-title":"Clin Rheumatol"},{"key":"9575_CR15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.autrev.2019.05.003","volume":"18","author":"E D\u2019Amico","year":"2019","unstructured":"D\u2019Amico E, Zangh\u00ec A, Gastaldi M, Patti F, Zappia M, Franciotta D (2019) Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: present and future perspectives. Autoimmun Rev 18:665\u2013672","journal-title":"Autoimmun Rev"},{"key":"9575_CR16","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood-2019-123949","volume":"134","author":"F Morschhauser","year":"2019","unstructured":"Morschhauser F, Carlo-Stella C, Offner F, Salles GA, Hutchings M, Iacoboni G, Sureda A, Crump M, Martinez-Lopez J, Thomas D (2019) Dual CD20-targeted therapy with concurrent CD20-TCB and obinutuzumab shows highly promising clinical activity and manageable safety in relapsed or refractory B-cell non-Hodgkin lymphoma: preliminary results from a phase Ib trial. Blood 134:1584","journal-title":"Blood"},{"key":"9575_CR17","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2217\/imt-2016-0003","volume":"8","author":"YM Pers","year":"2016","unstructured":"Pers YM, Jorgensen C (2016) Perspectives of Ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases. Immunotherapy 8:1091\u20131096","journal-title":"Immunotherapy"},{"key":"9575_CR18","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.3390\/jcm10245847","volume":"10","author":"L Del Vecchio","year":"2021","unstructured":"Del Vecchio L, Allinovi M, Rocco P, Brando B (2021) Rituximab therapy for adults with nephrotic syndromes: standard schedules or B cell-targeted therapy? J Clin Med 10:5847","journal-title":"J Clin Med"},{"key":"9575_CR19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3390\/jcm5120107","volume":"5","author":"D Chen","year":"2016","unstructured":"Chen D, Gallagher S, Monson NL, Herbst R, Wang Y (2016) Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies. J Clin Med 5:107","journal-title":"J Clin Med"},{"key":"9575_CR20","volume":"46","author":"SA Brod","year":"2020","unstructured":"Brod SA (2020) Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. Mult Scler Relat Disord 46:102538","journal-title":"Mult Scler Relat Disord"},{"key":"9575_CR21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1600-6143.2011.03833.x","volume":"12","author":"EG Kamburova","year":"2012","unstructured":"Kamburova EG, Koenen HJ, Boon L, Hilbrands LB, Joosten I (2012) In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant 12:341\u2013350","journal-title":"Am J Transplant"},{"key":"9575_CR22","first-page":"1","volume-title":"Antibody Fc","author":"VRG Rom\u00e1n","year":"2014","unstructured":"Rom\u00e1n VRG, Murray JC, Weiner LM (2014) Antibody-dependent cellular cytotoxicity (ADCC). Antibody Fc. Elsevier, pp 1\u201327"},{"key":"9575_CR23","first-page":"7","volume":"1","author":"D Zahavi","year":"2018","unstructured":"Zahavi D, AlDeghaither D, O\u2019Connell A, Weiner LM (2018) Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy. Antib Ther 1:7\u201312","journal-title":"Antib Ther"},{"key":"9575_CR24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000377675","volume":"73","author":"H von B\u00fcdingen","year":"2015","unstructured":"von B\u00fcdingen H, Palanichamy A, Lehmann-Horn K, Michel BA, Zamvil SS (2015) Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets. Eur Neurol 73:238\u2013246","journal-title":"Eur Neurol"},{"key":"9575_CR25","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1111\/bph.13780","volume":"174","author":"AL Nguyen","year":"2017","unstructured":"Nguyen AL, Gresle M, Marshall T, Butzkueven H, Field J (2017) Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies. Br J Pharmacol 174:1895\u20131907","journal-title":"Br J Pharmacol"},{"key":"9575_CR26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.imlet.2014.11.001","volume":"163","author":"C Cornaby","year":"2015","unstructured":"Cornaby C, Gibbons L, Mayhew V, Sloan CS, Welling A, Poole BD (2015) B cell epitope spreading: mechanisms and contribution to autoimmune diseases. Immunol Lett 163:56\u201368","journal-title":"Immunol Lett"},{"key":"9575_CR27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/antib9040068","volume":"9","author":"CS Zent","year":"2020","unstructured":"Zent CS, Pinney JJ, Chu CC, Elliott MR (2020) Complement activation in the treatment of B-cell malignancies. Antibodies 9:68","journal-title":"Antibodies"},{"key":"9575_CR28","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-chembioeng-100522-102155","author":"J Fine","year":"2024","unstructured":"Fine J, Meksiriporn B, Tan J, Spangler JB (2024) Mechanism-driven design of multispecific antibodies for targeted disease treatment. Annu Rev Chem Biomol Eng. https:\/\/doi.org\/10.1146\/annurev-chembioeng-100522-102155","journal-title":"Annu Rev Chem Biomol Eng"},{"key":"9575_CR29","volume":"12","author":"F Wu","year":"2021","unstructured":"Wu F, Gao J, Kang J, Wang X, Niu Q, Liu J, Zhang L (2021) B cells in rheumatoid arthritis: pathogenic mechanisms and treatment prospects. Front Immunol 12:750753","journal-title":"Front Immunol"},{"key":"9575_CR30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40744-015-0016-9","volume":"2","author":"MD Cohen","year":"2015","unstructured":"Cohen MD, Keystone E (2015) Rituximab for rheumatoid arthritis. Rheumatol Ther 2:99\u2013111","journal-title":"Rheumatol Ther"},{"key":"9575_CR31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/ar2852","volume":"11","author":"MJ Boumans","year":"2009","unstructured":"Boumans MJ, Tak PP (2009) Rituximab treatment in rheumatoid arthritis: how does it work? Arthritis Res Ther 11:134","journal-title":"Arthritis Res Ther"},{"key":"9575_CR32","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1007\/s10067-019-04699-8","volume":"38","author":"S Tavakolpour","year":"2019","unstructured":"Tavakolpour S, Alesaeidi S, Darvishi M, GhasemiAdl M, Darabi-Monadi S, Akhlaghdoust M, Elikaei Behjati S, Jafarieh A (2019) A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clin Rheumatol 38:2977\u20132994","journal-title":"Clin Rheumatol"},{"key":"9575_CR33","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.651323","volume":"9","author":"M Wennmann","year":"2021","unstructured":"Wennmann M, Kathemann S, Kampmann K, Ohlsson S, B\u00fcscher A, Holzinger D, Della Marina A, Lainka E (2021) A retrospective analysis of rituximab treatment for B cell depletion in different pediatric indications. Front Pediatr 9:651323","journal-title":"Front Pediatr"},{"key":"9575_CR34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4137\/CCRep.S15177","volume":"7","author":"M Adawi","year":"2014","unstructured":"Adawi M, Bisharat B, Bowirrat A (2014) Systemic Lupus Erythematosus (SLE) complicated by neuromyelitis optica (NMO - Devic\u2019s Disease): clinic-pathological report and review of the literature. Clin Med Insights Case Rep 7:41\u201347","journal-title":"Clin Med Insights Case Rep"},{"key":"9575_CR35","doi-asserted-by":"crossref","first-page":"1129906","DOI":"10.3389\/fimmu.2023.1129906","volume":"14","author":"MJ Furman","year":"2023","unstructured":"Furman MJ, Meuth SG, Albrecht P, Dietrich M, Blum H, Mares J, Milo R, Hartung HP (2023) B cell targeted therapies in inflammatory autoimmune disease of the central nervous system. Front Immunol 14:1129906","journal-title":"Front Immunol"},{"key":"9575_CR36","doi-asserted-by":"crossref","first-page":"6268","DOI":"10.3390\/jcm12196268","volume":"12","author":"I Parodis","year":"2023","unstructured":"Parodis I, Long X, Karlsson MCI, Huang X (2023) B cell tolerance and targeted therapies in SLE. J Clin Med 12:6268","journal-title":"J Clin Med"},{"key":"9575_CR37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/TCRM.S252592","volume":"17","author":"A Bag-Ozbek","year":"2021","unstructured":"Bag-Ozbek A, Hui-Yuen JS (2021) Emerging B-cell therapies in systemic lupus erythematosus. Ther Clin Risk Manage 17:39\u201354","journal-title":"Ther Clin Risk Manage"},{"key":"9575_CR38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/08916934.2019.1700232","volume":"53","author":"Y Feng","year":"2020","unstructured":"Feng Y, Yang M, Wu H, Lu Q (2020) The pathological role of B cells in systemic lupus erythematosus: from basic research to clinical. Autoimmunity 53:56\u201364","journal-title":"Autoimmunity"},{"key":"9575_CR39","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.biocel.2009.10.011","volume":"42","author":"E Nashi","year":"2010","unstructured":"Nashi E, Wang Y, Diamond B (2010) The role of B cells in lupus pathogenesis. Int J Biochem Cell Biol 42:543\u2013550","journal-title":"Int J Biochem Cell Biol"},{"key":"9575_CR40","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.it.2017.02.001","volume":"38","author":"PA Morawski","year":"2017","unstructured":"Morawski PA, Bolland S (2017) Expanding the B cell-centric view of systemic lupus erythematosus. Trends Immunol 38:373\u2013382","journal-title":"Trends Immunol"},{"key":"9575_CR41","volume":"15","author":"N Abid","year":"2023","unstructured":"Abid N, Manaye S, Naushad H, Cheran K, Murthy C, Bornemann EA, Kamma HK, Alabbas M, Elashahab M (2023) The safety and efficacy of rituximab and belimumab in systemic lupus erythematosus: a systematic review. Cureus 15:e40719","journal-title":"Cureus"},{"key":"9575_CR42","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/1744666X.2017.1259068","volume":"13","author":"P Mota","year":"2017","unstructured":"Mota P, Reddy V, Isenberg D (2017) Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis. Expert Rev Clin Immunol 13:667\u2013676","journal-title":"Expert Rev Clin Immunol"},{"key":"9575_CR43","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3389\/fmed.2020.00316","volume":"7","author":"I Parodis","year":"2020","unstructured":"Parodis I, Stockfelt M, Sj\u00f6wall C (2020) B cell therapy in systemic lupus erythematosus: from rationale to clinical practice. Front Med 7:316","journal-title":"Front Med"},{"key":"9575_CR44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coi.2018.10.008","volume":"55","author":"M Hale","year":"2018","unstructured":"Hale M, Rawlings DJ, Jackson SW (2018) The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy. Curr Opin Immunol 55:81\u201388","journal-title":"Curr Opin Immunol"},{"key":"9575_CR45","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1186\/s13063-022-06874-w","volume":"23","author":"M van Schaik","year":"2022","unstructured":"van Schaik M, Arends EJ, Soonawala D, van Ommen E, de Leeuw K, Limper M, van Paassen P, Huizinga TWJ, Toes REM, van Kooten C, Rotmans JI, Rabelink TJ, Teng YKO (2022) Efficacy of Belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial. Trials 23:939","journal-title":"Trials"},{"key":"9575_CR46","first-page":"310ra166","volume":"7","author":"R Li","year":"2015","unstructured":"Li R, Rezk A, Miyazaki Y, Hilgenberg E, Touil H, Shen P, Moore CS, Michel L, Althekair F, Rajasekharan S (2015) Proinflammatory GM-CSF\u2013producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med 7:310ra166","journal-title":"Sci Transl Med"},{"key":"9575_CR47","doi-asserted-by":"crossref","first-page":"e918","DOI":"10.1212\/NXI.0000000000000918","volume":"8","author":"J Graf","year":"2020","unstructured":"Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil SS, Hartung H-P (2020) Targeting B cells to modify MS, NMOSD, and MOGAD: part 1. Neurol Neuroimmunol Neuroinflamm 8:e918","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"9575_CR48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25927","volume":"89","author":"G Comi","year":"2021","unstructured":"Comi G, Bar-Or A, Lassmann H, Uccelli A, Hartung HP, Montalban X, S\u00f8rensen PS, Hohlfeld R, Hauser SL (2021) Role of B cells in multiple sclerosis and related disorders. Ann Neurol 89:13\u201323","journal-title":"Ann Neurol"},{"key":"9575_CR49","doi-asserted-by":"crossref","first-page":"22932","DOI":"10.1073\/pnas.2008523117","volume":"117","author":"A Ramesh","year":"2020","unstructured":"Ramesh A, Schubert RD, Greenfield AL, Dandekar R, Loudermilk R, Sabatino JJ Jr, Koelzer MT, Tran EB, Koshal K, Kim K (2020) A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. Proc Natl Acad Sci 117:22932\u201322943","journal-title":"Proc Natl Acad Sci"},{"key":"9575_CR50","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3389\/fimmu.2020.00760","volume":"11","author":"J Van Langelaar","year":"2020","unstructured":"Van Langelaar J, Rijvers L, Smolders J, Van Luijn MM (2020) B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers. Front Immunol 11:760","journal-title":"Front Immunol"},{"key":"9575_CR51","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40263-021-00843-8","volume":"35","author":"A Bar-Or","year":"2021","unstructured":"Bar-Or A, O\u2019Brien SM, Sweeney ML, Fox EJ, Cohen JA (2021) Clinical perspectives on the molecular and pharmacological attributes of anti-CD20 therapies for multiple sclerosis. CNS Drugs 35:985\u2013997","journal-title":"CNS Drugs"},{"key":"9575_CR52","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2147\/TCRM.S282390","volume":"17","author":"CR Mancinelli","year":"2021","unstructured":"Mancinelli CR, Rossi N, Capra R (2021) Ocrelizumab for the treatment of multiple sclerosis: safety, efficacy, and pharmacology. Ther Clin Risk Manage 17:765\u2013776","journal-title":"Ther Clin Risk Manage"},{"key":"9575_CR53","doi-asserted-by":"crossref","first-page":"163","DOI":"10.18071\/isz.75.0163","volume":"75","author":"D Pukoli","year":"2022","unstructured":"Pukoli D, V\u00e9csei L (2022) B-cell depletion in the therapy of multiple sclerosis: Ofatumumab is a new player. Ideggyogyaszati szemle 75:163\u2013169","journal-title":"Ideggyogyaszati szemle"},{"key":"9575_CR54","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41573-022-00477-5","volume":"21","author":"L Bierhansl","year":"2022","unstructured":"Bierhansl L, Hartung HP, Aktas O, Ruck T, Roden M, Meuth SG (2022) Thinking outside the box: non-canonical targets in multiple sclerosis. Nat Rev Drug Discovery 21:578\u2013600","journal-title":"Nat Rev Drug Discovery"},{"key":"9575_CR55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25119","volume":"83","author":"AL Greenfield","year":"2018","unstructured":"Greenfield AL, Hauser SL (2018) B-cell therapy for multiple sclerosis: entering an era. Ann Neurol 83:13\u201326","journal-title":"Ann Neurol"},{"key":"9575_CR56","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","volume":"14","author":"JM Gelfand","year":"2017","unstructured":"Gelfand JM, Cree BAC, Hauser SL (2017) Ocrelizumab and other CD20(+) B-cell-depleting therapies in multiple sclerosis. Neurotherapeutics 14:835\u2013841","journal-title":"Neurotherapeutics"},{"key":"9575_CR57","volume":"130","author":"S-H Kim","year":"2019","unstructured":"Kim S-H, Hyun J-W, Kim HJ (2019) Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder. Neurochem Int 130:104347","journal-title":"Neurochem Int"},{"key":"9575_CR58","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3324\/haematol.2019.218883","volume":"104","author":"E Lucchini","year":"2019","unstructured":"Lucchini E, Zaja F, Bussel J (2019) Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? Haematologica 104:1124\u20131135","journal-title":"Haematologica"},{"key":"9575_CR59","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","volume":"17","author":"K Esfahani","year":"2020","unstructured":"Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, Miller WH Jr, Calabrese L (2020) Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol 17:504\u2013515","journal-title":"Nat Rev Clin Oncol"},{"key":"9575_CR60","doi-asserted-by":"crossref","first-page":"2149675","DOI":"10.1002\/eji.202149675","volume":"53","author":"A Merino-Vico","year":"2023","unstructured":"Merino-Vico A, Frazzei G, van Hamburg JP, Tas SW (2023) Targeting B cells and plasma cells in autoimmune diseases: from established treatments to novel therapeutic approaches. Eur J Immunol 53:2149675","journal-title":"Eur J Immunol"},{"key":"9575_CR61","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/0961203320982668","volume":"30","author":"M Leandro","year":"2021","unstructured":"Leandro M, Isenberg DA (2021) Rituximab-The first twenty years. Lupus 30:371\u2013377","journal-title":"Lupus"},{"key":"9575_CR62","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/pharmaceutics16010120","volume":"16","author":"CY Lee","year":"2024","unstructured":"Lee CY, Chan KH (2024) Personalized use of disease-modifying therapies in multiple sclerosis. Pharmaceutics 16:120","journal-title":"Pharmaceutics"},{"key":"9575_CR63","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1017\/cjn.2022.60","volume":"50","author":"P Kanatas","year":"2023","unstructured":"Kanatas P, Stouras I, Stefanis L, Stathopoulos P (2023) B-cell-directed therapies: a new era in multiple sclerosis treatment. Can J Neurol Sci 50:355\u2013364","journal-title":"Can J Neurol Sci"},{"key":"9575_CR64","doi-asserted-by":"crossref","first-page":"1103307","DOI":"10.3389\/fimmu.2023.1103307","volume":"14","author":"Z-y Li","year":"2023","unstructured":"Li Z-y, Cai M-L, Qin Y, Chen Z (2023) Age\/autoimmunity-associated B cells in inflammatory arthritis: an emerging therapeutic target. Front Immunol 14:1103307","journal-title":"Front Immunol"},{"key":"9575_CR65","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104701","volume":"94","author":"P Maggi","year":"2023","unstructured":"Maggi P, Bulcke CV, Pedrini E, Bugli C, Sellimi A, Wynen M, St\u00f6lting A, Mullins WA, Kalaitzidis G, Lolli V, Perrotta G, El Sankari S, Duprez T, Li X, Calabresi PA, van Pesch V, Reich DS, Absinta M (2023) B cell depletion therapy does not resolve chronic active multiple sclerosis lesions. EBioMedicine 94:104701","journal-title":"EBioMedicine"},{"key":"9575_CR66","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2217\/ijr.12.7","volume":"7","author":"DR Chen","year":"2012","unstructured":"Chen DR, Cohen PL (2012) Living life without B cells: is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis? Int J Clin Rheumatol 7:159\u2013166","journal-title":"Int J Clin Rheumatol"},{"key":"9575_CR67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009708","volume":"17","author":"V Upasani","year":"2021","unstructured":"Upasani V, Rodenhuis-Zybert I, Cantaert T (2021) Antibody-independent functions of B cells during viral infections. PLoS Pathog 17:e1009708","journal-title":"PLoS Pathog"},{"key":"9575_CR68","doi-asserted-by":"crossref","first-page":"1006477","DOI":"10.3389\/fonc.2022.1006477","volume":"12","author":"H Wu","year":"2022","unstructured":"Wu H, Chen C, Gu L, Li J, Yue Y, Lyu M, Cui Y, Zhang X, Liu Y, Zhu H, Liao X, Zhang T, Sun F, Hu W (2022) B cell deficiency promotes the initiation and progression of lung cancer. Front Oncol 12:1006477","journal-title":"Front Oncol"},{"key":"9575_CR69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-020-00167-1","volume":"9","author":"RS Risbjerg","year":"2020","unstructured":"Risbjerg RS, Hansen MV, S\u00f8rensen AS, Kragstrup TW (2020) The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. Exp Hematol Oncol 9:1\u20133","journal-title":"Exp Hematol Oncol"},{"key":"9575_CR70","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2217\/imt-2017-0178","volume":"10","author":"KA Sacco","year":"2018","unstructured":"Sacco KA, Abraham RS (2018) Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution. Immunotherapy 10:713\u2013728","journal-title":"Immunotherapy"},{"key":"9575_CR71","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41569-018-0106-9","volume":"16","author":"AP Sage","year":"2019","unstructured":"Sage AP, Tsiantoulas D, Binder CJ, Mallat Z (2019) The role of B cells in atherosclerosis. Nat Rev Cardiol 16:180\u2013196","journal-title":"Nat Rev Cardiol"},{"key":"9575_CR72","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s11886-022-01722-4","volume":"24","author":"K Bermea","year":"2022","unstructured":"Bermea K, Bhalodia A, Huff A, Rousseau S, Adamo L (2022) The role of B cells in cardiomyopathy and heart failure. Curr Cardiol Rep 24:935\u2013946","journal-title":"Curr Cardiol Rep"},{"key":"9575_CR73","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1310\/sci2404-379","volume":"24","author":"MS Nash","year":"2018","unstructured":"Nash MS, Groah SL, Gater DR Jr, Dyson-Hudson TA, Lieberman JA, Myers J, Sabharwal S, Taylor AJ (2018) Identification and management of cardiometabolic risk after spinal cord injury: clinical practice guideline for health care providers. Top Spinal Cord Inj Rehabil 24:379\u2013423","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"9575_CR74","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","volume":"14","author":"JM Gelfand","year":"2017","unstructured":"Gelfand JM, Cree BA, Hauser SL (2017) Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis. Neurotherapeutics 14:835\u2013841","journal-title":"Neurotherapeutics"},{"key":"9575_CR75","volume":"11","author":"M Sadeghi Haddad Zavareh","year":"2023","unstructured":"Sadeghi Haddad Zavareh M, Mehdinezhad H, Mehraeen R, Golparvar Azizi M, Tavakoli Pirzaman A (2023) Pneumocystis jirovecii pneumonia complicated a case of SARS-CoV-2 infection and multiple sclerosis after treatment with rituximab. Clin Case Rep 11:e7455","journal-title":"Clin Case Rep"},{"key":"9575_CR76","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijtb.2019.08.003","volume":"67","author":"S Pandey","year":"2020","unstructured":"Pandey S, Ghosh S, Halder P, Pal D, Modak DC, Guha SK (2020) Pulmonary tuberculosis and pneumocystis jirovecii concurrent pneumonia in HIV infected patients at a resource limited setting in Eastern India: a case series. Indian J Tuberc 67:378\u2013382","journal-title":"Indian J Tuberc"},{"key":"9575_CR77","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102195","volume":"43","author":"F Safavi","year":"2020","unstructured":"Safavi F, Nourbakhsh B, Azimi AR (2020) B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord 43:102195","journal-title":"Mult Scler Relat Disord"},{"key":"9575_CR78","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00103-20","author":"N Clementi","year":"2021","unstructured":"Clementi N, Ghosh S, De Santis M, Castelli M, Criscuolo E, Zanoni I, Clementi M, Mancini N (2021) Viral respiratory pathogens and lung injury. Clin Microbiol Rev. https:\/\/doi.org\/10.1128\/CMR.00103-20","journal-title":"Clin Microbiol Rev"},{"key":"9575_CR79","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, Fragoso-Loyo H, Zuta-Santillan E, Schindler T, Brunetta P (2022) B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81:100\u2013107","journal-title":"Ann Rheum Dis"},{"key":"9575_CR80","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fimmu.2017.00234","volume":"8","author":"C Morath","year":"2017","unstructured":"Morath C, Zeier M, D\u00f6hler B, Opelz G, S\u00fcsal C (2017) ABO-incompatible kidney transplantation. Front Immunol 8:234","journal-title":"Front Immunol"},{"key":"9575_CR81","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104490","volume":"70","author":"F Ladeira","year":"2023","unstructured":"Ladeira F, Oliveira T, Soares M, Araujo C, Sousa A, Brum M, Sequeira J, Capela C (2023) HBV and VZV seroprotection loss in MS patients under DMT. Mult Scler Relat Disord 70:104490","journal-title":"Mult Scler Relat Disord"},{"key":"9575_CR82","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1007\/s00415-022-11009-x","volume":"269","author":"AR Buonomo","year":"2022","unstructured":"Buonomo AR, Viceconte G, Calabrese M, De Luca G, Tomassini V, Cavalla P, Maniscalco GT, Ferraro D, Nociti V, Radaelli M, Buscarinu MC, Paolicelli D, Gajofatto A, Annovazzi P, Pinardi F, Di Filippo M, Cordioli C, Zappulo E, Scotto R, Gentile I, Spiezia AL, Petruzzo M, De Angelis M, Brescia Morra V, Solaro C, Gasperini C, Cocco E, Moccia M, Lanzillo R (2022) Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. J Neurol 269:3301\u20133307","journal-title":"J Neurol"},{"key":"9575_CR83","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1111\/ajt.15514","volume":"19","author":"RR Redfield","year":"2019","unstructured":"Redfield RR, Jordan SC, Busque S, Vincenti F, Woodle ES, Desai N, Reed EF, Tremblay S, Zachary AA, Vo AA (2019) Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. Am J Transplant 19:3035\u20133045","journal-title":"Am J Transplant"},{"key":"9575_CR84","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","volume":"49","author":"I Los-Arcos","year":"2021","unstructured":"Los-Arcos I, Iacoboni G, Aguilar-Guisado M, Alsina-Manrique L, D\u00edaz de Heredia C, Fortuny-Guasch C, Garc\u00eda-Cadenas I, Garc\u00eda-Vidal C, Gonz\u00e1lez-Vicent M, Hernani R, Kwon M, Machado M, Mart\u00ednez-G\u00f3mez X, Maldonado VO, Pla CP, Pi\u00f1ana JL, Pomar V, Reguera-Ortega JL, Salavert M, Soler-Palac\u00edn P, V\u00e1zquez-L\u00f3pez L, Barba P, Ruiz-Camps I (2021) Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection 49:215\u2013231","journal-title":"Infection"},{"key":"9575_CR85","first-page":"625","volume-title":"Seminars in arthritis and rheumatism","author":"D Daoussis","year":"2017","unstructured":"Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, Georgiou P, Andonopoulos AP, Drosos AA, Sakkas L (2017) A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Seminars in arthritis and rheumatism. Elsevier, pp 625\u2013631"},{"key":"9575_CR86","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1172\/JCI85113","volume":"127","author":"C Mauri","year":"2017","unstructured":"Mauri C, Menon M (2017) Human regulatory B cells in health and disease: therapeutic potential. J Clin Investig 127:772\u2013779","journal-title":"J Clin Investig"},{"key":"9575_CR87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0586-0","volume":"7","author":"J Davda","year":"2019","unstructured":"Davda J, Declerck P, Hu-Lieskovan S, Hickling TP, Jacobs IA, Chou J, Salek-Ardakani S, Kraynov E (2019) Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. J Immunother Cancer 7:1\u20139","journal-title":"J Immunother Cancer"},{"key":"9575_CR88","doi-asserted-by":"crossref","unstructured":"Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA, Haile A, Huang K, Kinnett B, Liebeskind MJ (2021) Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. MedRxiv","DOI":"10.1101\/2021.04.05.21254656"},{"key":"9575_CR89","volume":"13","author":"HC Ertl","year":"2022","unstructured":"Ertl HC (2022) Immunogenicity and toxicity of AAV gene therapy. Front Immunol 13:975803","journal-title":"Front Immunol"},{"key":"9575_CR90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190425","volume":"13","author":"AB Memon","year":"2018","unstructured":"Memon AB, Javed A, Caon C, Srivastawa S, Bao F, Bernitsas E, Chorostecki J, Tselis A, Seraji-Bozorgzad N, Khan O (2018) Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS ONE 13:e0190425","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"9575_CR91","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar3910","volume":"15","author":"V Reddy","year":"2013","unstructured":"Reddy V, Jayne D, Close D, Isenberg D (2013) B-cell depletion in SLE: clinical and trial experience with rituximab and Ocrelizumab and implications for study design. Arthritis Res Ther 15(Suppl 1):S2","journal-title":"Arthritis Res Ther"},{"key":"9575_CR92","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","volume":"77","author":"S Brauner","year":"2020","unstructured":"Brauner S, Eriksson-Dufva A, Hietala MA, Frisell T, Press R, Piehl F (2020) Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol 77:974\u2013981","journal-title":"JAMA Neurol"},{"key":"9575_CR93","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Fo\u00e0 R, Maurer J, O\u2019Brien S, Valente N, Wenger M, Maloney DG (2017) Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther 34:2232\u20132273","journal-title":"Adv Ther"},{"key":"9575_CR94","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nri.2017.24","volume":"17","author":"DJ Rawlings","year":"2017","unstructured":"Rawlings DJ, Metzler G, Wray-Dutra M, Jackson SW (2017) Altered B cell signalling in autoimmunity. Nat Rev Immunol 17:421\u2013436","journal-title":"Nat Rev Immunol"},{"key":"9575_CR95","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41416-022-02038-4","volume":"128","author":"J Cuzick","year":"2023","unstructured":"Cuzick J (2023) The importance of long-term follow up of participants in clinical trials. Br J Cancer 128:432\u2013438","journal-title":"Br J Cancer"},{"key":"9575_CR96","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41584-019-0211-0","volume":"15","author":"SJS Rubin","year":"2019","unstructured":"Rubin SJS, Bloom MS, Robinson WH (2019) B cell checkpoints in autoimmune rheumatic diseases. Nat Rev Rheumatol 15:303\u2013315","journal-title":"Nat Rev Rheumatol"},{"key":"9575_CR97","first-page":"191","volume":"6","author":"S Akhondzadeh","year":"2014","unstructured":"Akhondzadeh S (2014) Personalized medicine: a tailor made medicine. Avicenna J Med Biotechnol 6:191","journal-title":"Avicenna J Med Biotechnol"},{"key":"9575_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11111181","author":"R D\u00edaz-Pe\u00f1a","year":"2021","unstructured":"D\u00edaz-Pe\u00f1a R (2021) Personalized Medicine in Autoimmune Diseases. J Pers Med. https:\/\/doi.org\/10.3390\/jpm11111181","journal-title":"J Pers Med"},{"key":"9575_CR99","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102398","volume":"45","author":"M Rolfes","year":"2020","unstructured":"Rolfes M, Rutatangwa A, Waubant E, Krysko KM (2020) Ocrelizumab exposure in the second trimester of pregnancy without neonatal B-cell depletion. Mult Scler Relat Disord 45:102398","journal-title":"Mult Scler Relat Disord"},{"key":"9575_CR100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-981-15-3532-1_11","volume-title":"B cells in immunity and tolerance","author":"X Lin","year":"2020","unstructured":"Lin X, Lu L (2020) B cell-mediated autoimmune diseases. B cells in immunity and tolerance. Springer Nature, pp 145\u2013160"},{"key":"9575_CR101","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/OTT.S370880","volume":"16","author":"T Shrivastava","year":"2023","unstructured":"Shrivastava T, Van Rhee F, Al Hadidi S (2023) Targeting B cell maturation antigen in patients with multiple myeloma: current perspectives. Onco Targets Ther 16:441\u2013464","journal-title":"Onco Targets Ther"}],"updated-by":[{"DOI":"10.1007\/s11033-024-09735-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000}}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09575-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-09575-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09575-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T03:08:47Z","timestamp":1738724927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-09575-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9575"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-09575-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11033-024-09735-8","asserted-by":"object"}]},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]},"assertion":[{"value":"26 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11033-024-09735-8","URL":"https:\/\/doi.org\/10.1007\/s11033-024-09735-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"629"}}